Takeda Pharmaceutical Company Limited

Scohia Pharma, Inc.

Yasuhiro Hirata

Yasufumi Miyamoto

Takaharu Hirayama

Seiji Miwatashi

Yuko Hitomi

Shinichi Imamura

Tomohiro Okawa

Moriteru Asano

Naoki Iwamura

Koji Watanabe

Nobuyuki Takakura

Hideki Furukawa

Masanori Okaniwa

Akito Shibuya

Jumpei Aida

Douglas Robert Cary

Jun Fujimoto

Naoyoshi Noguchi

Koji Ono

Masahiro Ito

Toshio Tanaka

Takeshi Yamasaki

Hideo Suzuki

Takuto Kojima

Hidekazu Tokuhara

Hiroshi Banno

Tsuyoshi Maekawa

Yasuyoshi Arikawa

Hironobu Maezaki

Yasutomi Asano

Terufumi Takagi

Shizuo Kasai

Shuji Kitamura

Tzu-Tshin Wong

Toshitake Kobayashi

Yusuke Sasaki

Yasuhiro Imaeda

Nobuki Sakauchi

Yusuke Tominari

Osamu Kurasawa

Yuta Tanaka

Nobuo Cho

Ryo Mizojiri

Kazuko Yonemori

Akinori Toita

Yayoi Nakayama

Hironori Kokubo

Ryosuke Arai

Nao Morishita

Bunnai Saito

Osamu Sano

Satoshi Sasaki

Masato Yoshida

Norihito Tokunaga

Kazuaki Takami

Shigemitsu Matsumoto

Takashi Ichikawa

Yayoi Yoshitomi

Arai Ryosuke

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

Aromatic compound

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy. 

Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic amide compound

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Aromatic compounds with GPR40 agonistic activity

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Aromatic ring compound

Growing community of inventors

Kanagawa, Japan

Yasuhiro Hirata